At the Extraordinary General Meeting in Oasmia Pharmaceutical AB (the ”company”) held on 21 February 2022, the resolutions below were made. All resolutions were in accordance with the submitted proposals, described in detail in the general meeting documents available at the company’s website,

Resolution on amendment of the Articles of Association
The general meeting resolved on an amendment to the Articles of Association whereby the company’s corporate name is changed to “Vivesto AB”.

Until the new Articles of Association have been registered by the Swedish Companies Registration Office (Sw. Bolagsverket), the company will use the current corporate name Oasmia Pharmaceutical AB.

Resolution on approval of the Board of Directors’ resolution on new issue of shares with preferential rights for existing shareholders
The general meeting resolved to approve the Board of Directors’ resolution on 19 January 2022 on a new issue, with preferential rights for the shareholders, of no more than 89,673,909 shares, entailing an increase in the share capital of no more than SEK 8,967,390.90. The right to subscribe for shares shall, with preferential rights for existing shareholders, be granted to those who, on the record date of the rights issue on 4 March 2022, are registered as shareholders in the company. Each shareholder receives one (1) subscription right for each (1) existing share. Five (5) subscription rights entitle to subscription of one (1) share. Subscription of shares shall be made from and including 8 March 2022 until and including 22 March 2022 at a subscription price of SEK 1.68 per share.

For more information:
Francois Martelet, Chief Executive Officer
Phone: +46 18-50 54 40

About Oasmia Pharmaceutical AB
Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Oasmia’s shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit